Organoids represent a transformative advancement in cancer biology, offering a sophisticated three-dimensional model derived from human stem cells, organ-specific progenitor cells, and dissociated tumor tissues. These structures have become pivotal tools in biomarker discovery, drug screening, cell therapy, genetic engineering, immune research, and tissue regeneration. Unlike traditional models, cancer organoids capture the clinical heterogeneity of tumors and provide insights into drug sensitivities, underscoring the potential for personalized treatment strategies. Recent studies have demonstrated that organoids possess superior sensitivity, specificity, and predictive capabilities compared to conventional cell and animal models. Developing organoids-on-a-chip technology further enhances their utility by simulating the tumor microenvironment and facilitating interactions between multiple organs and tissues, thus enabling large-scale, high-throughput drug screening. Despite these advancements, there remains a need for further exploration into the integration of organoid technology with genomic and transcriptomic data to better understand drug resistance mechanisms and improve therapeutic outcomes.
This research topic aims to explore the latest advancements in the application of cancer organoids for drug screening and clinical trials. We seek to address key questions such as how organoids can be utilized to guide clinical medication and personalized treatment, and how they can improve the success rates of preclinical trials. Additionally, we aim to investigate the potential of combining organoid technology with CRISPR/Cas9 to uncover mechanisms of drug resistance and develop more effective anti-tumor therapies. By gathering and evaluating recent studies, we hope to provide fresh insights into the role of organoids in accelerating new drug development and precision medicine in cancer research.
To gather further insights in the application of organoids in cancer biology and drug screening, we welcome articles addressing, but not limited to, the following themes:
- Cancer Organoids as Advanced Models for Drug Screening.
- Advances in Organoids for Cancer Modeling and Therapeutic Applications.
- Organoid Technology and Tumor Precision Medicine.
- Cancer Organoids-on-a-chip for Cancer Immunotherapy.
- Advancements in Organoids and Spatiotemporal Omics: Unveiling Mechanistic Insights and Targeted Therapies for Cancer.
- Organoids for Regenerative Medicine.
- Organoids as Model Systems for Human Development, Disease, and Clinical Applications.
We accept different article types including Mini-Reviews, Brief Research Reports, and Perspectives. A full list of accepted article types, including descriptions, can be found at this link.
Please note: studies consisting solely of bioinformatic investigation of publicly available genomic/transcriptomic/proteomic data do not fall within the scope of the section unless they are expanded and provide significant biological or mechanistic insight into the process being studied.
Keywords: organoids, cancer biology, drug screening, precision medicine, clinical trials, biomarkers
Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
